Adaptive radiation boost study for rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether giving an extra, targeted radiation dose (adaptive radiation boost) after standard treatment can improve outcomes for people with rectal cancer. You may be eligible if you have stage T2-3 N0-1 rectal cancer and can undergo MRI scans and certain chemotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer).
- Your cancer is stage T2-3, N0-1, M0 (not spread to distant organs).
- You are willing to have MRI scans and CT scans (or PET-CT) for staging.
- You are at least 18 years old and in good enough health to have daily activities (ECOG 0 or 1).
- Your blood counts and liver function are within normal limits.
- You can take the chemotherapy drugs capecitabine and FOLFOX (or 5-FU or capecitabine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving radiation therapy before surgery for rectal cancer. It uses a higher dose to the tumor during standard radiation to see if it can improve outcomes.
This trial tests a personalized approach to treating rectal cancer before surgery. Doctors will adjust radiation therapy during treatment based on how well your tumor is shrinking, combined with chemotherapy drugs to improve outcomes.
This study looks at whether two different added “boosts” of radiation can work as well for rectal cancer patients, aiming to avoid or reduce the need for rectal cancer surgery. You would receive a specific combination of radiation (including brachytherapy) and chemotherapy, and your tumor’s location and size will determine if you can take part.
This Phase 1 study tests a radiation treatment approach guided by MRI scans to help keep nearby organs functioning while treating rectal cancer. It is designed to find a safe, effective way to target the tumor and adjust treatment during the course of therapy.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This trial tests whether radiation therapy can be adjusted each session using MRI images to better target rectal cancer while sparing healthy tissue. It's for patients with stage II or III rectal cancer that hasn't spread to other parts of the body.
Hear when a new Rectum Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.